Karyopharm Therap

Q2 FY2026 EarningsQ2 FY26 results exceeded revenue expectations with total sales of $33.4M vs. $32.2M consensus. U.S. XPOVIO net product revenue grew 4% YoY to $30.8M, showing resilience in a competitive myeloma market. While the GAAP net loss of $67.0M ($2.32 per share) was wider than expected due to non-cash derivative remeasurements, the operating loss improved to $22.5M, beating the -$28.3M consensus due to successful cost containment. The company remains on track for an August myelofibrosis sNDA submission, providing a critical near-term catalyst.